The company
behind your programs
Programs run on people. Meet ours.
One strong legacy, redesigned as the next generation of biosimilar execution.
Polpharma Biologics is built for speed, flexibility, and smart execution.
From Zug, Switzerland, we take programs from concept to commercial supply.
In-house leadership directing a partner network as one system.
Purpose-built
for partners
Biologic medicines can change lives, but only if patients can reliably access them. Our purpose is to expand access to high-quality biologic therapies by building biosimilars designed for durability, affordability, and long-term supply.
Development & Manufacturing
Clinical development
Regulatory affairs
Quality
PM, ALM, LCM, IP
The people behind
the programs
Board of Directors
Enterprise
Business
Technology
Proven in practice. A track record built over decades of GMP and regulatory delivery.
Our efficient operating model advances biosimilar programs and supports partners through approval and long-term supply.
Decades of GMP manufacturing, regulatory expertise, and global partnerships, built through Polpharma.
Entry into biologics, with dedicated R&D and development capabilities established to advance biosimilar programs
First out-licensing agreements signed for biosimilar programs
Regulatory filings submitted for lead biosimilars, Ranibizumab and Natalizumab
First regulatory approvals and commercial launches of Ranibizumab and Natalizumab in key markets.
Global rollout of approved biosimilars, with the pipeline strengthened by additional molecules.
How we behave
when it matters most.
Velocity
Focus and urgency in practice. We make clear decisions and move programs forward with purpose.
Impact
We prioritize meaningful value, work that expands access and strengthens healthcare systems.
Belonging
We foster trusted relationships across teams and partners, strengthening outcomes through collaboration.
Empowerment
We place ownership in the hands of experienced people and support them to lead with accountability and confidence.
Let's build together.
If you want to explore what a partnership with us could look like, we're ready to talk.